This is a numbers-first look at Neuland Laboratories Limited (NEULANDLAB), covering income trends, margins, valuation, and shareholding.
Neuland Revenue Trend
Revenue slipped 4.7% to ₹1,497 Cr in FY2025 — a step back from the ₹1,571 Cr Neuland Laboratories Limited recorded in FY2024.
Stepping back, the 10-year revenue CAGR of 12.3% tells a positive story. Neuland Laboratories Limited has been growing at a solid clip.
With a top line of ₹1,497 Cr, Neuland Laboratories Limited operates at a mid-sized scale within the pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,497 Cr | -4.7% |
| FY2024 | ₹1,571 Cr | +30.8% |
| FY2023 | ₹1,201 Cr | +26.0% |
| FY2022 | ₹953 Cr | +1.7% |
| FY2021 | ₹937 Cr | — |
View Neuland Laboratories Limited's full 10-year revenue trend with CAGR analysis →
Neuland Profitability
Neuland Laboratories Limited's profitability took a step back in FY2025, with net income falling 13.3% to ₹260 Cr.
Net margin slipped from 19.1% to 17.4% in FY2025 — a sign of thinning profitability.
Diluted EPS stood at ₹202.74 in FY2025, compared to ₹233.89 in FY2024.
Is Neuland Undervalued
Running the numbers through the P/E Ratio model gives a fair value of ₹7,036 for Neuland Laboratories Limited.
Neuland Laboratories Limited shares are currently trading at ₹16,992.00.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹7,036 | 58.6% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Neuland Laboratories Limited with detailed assumptions →
Neuland Shareholding Pattern
Promoter holding is steady at 32.6% — no buying or selling over the past 4 quarters.
As of March 2026, FIIs own 20.5% of the company — down from 21.7% a year earlier.
Domestic institutions moved their stake up to 15.8% from 11.6% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 32.6% | 20.5% | 15.8% | 31.1% |
| Dec 2025 | 32.6% | 20.9% | 14.7% | 31.8% |
| Sep 2025 | 32.6% | 20.6% | 13.5% | 32.8% |
| Jun 2025 | 32.7% | 21.7% | 11.6% | 33.7% |
Track quarterly shareholding changes for Neuland Laboratories Limited →
Neuland Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹21.80B (up 19.0% YoY from ₹18.33B).
Top categories: Property, Plant & Equipment (32.0%), Inventories (17.7%), Receivables (14.5%).
Of the ₹21.80B in liabilities and equity, 69.9% is shareholder equity, 7.2% is interest-bearing debt, and 22.8% is operating liabilities. Over the year, debt is up 64.7% and equity is up 18.9%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 2.40B |
| Receivables | 3.16B |
| Inventories | 3.86B |
| Property, Plant & Equipment | 6.98B |
| Investments | 15.29M |
| Intangibles & Goodwill | 2.81B |
| Other Assets | 2.58B |
| Category | Value |
|---|---|
| Equity | 15.25B |
| Short-term Debt | 477.93M |
| Long-term Debt | 1.09B |
| Trade Payables | 2.52B |
| Other Liabilities | 2.46B |
Neuland — The Bottom Line
What should investors take away from Neuland Laboratories Limited's (NEULANDLAB) latest numbers? Here's the summary.
Revenue of ₹1,497 Cr in FY2025, down 4.7% year-over-year.
Long-term revenue has been compounding at 12.3% annually over 10 years.
The company is profitable, with a net margin of 17.4% and net income of ₹260 Cr.
The P/E Ratio model implies 58.6% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Neuland Laboratories Limited.